{"success":true,"data":{"pressRelease":{"id":"46113","rtpr_id":"nGNXbHXx7k","ticker":"TLX","exchange":"NASDAQ","all_tickers":["TLX"],"title":"Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences","author":"Globe Newswire","published_at":"2026-05-27T11:00:02.592Z","article_body":"MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix\nPharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr.\nChristian Behrenbruch, Managing Director and Group CEO, will participate in\nthe upcoming William Blair 46(th) Annual Growth Stock Conference in Chicago,\nIL and in the Jefferies Global Healthcare Conference in New York, NY.\n\nPresentation details:\n\nWilliam Blair 46th Annual Growth Stock Conference\nDate: June 2, 2026\nTime: 8:00 a.m. CDT (9:00 a.m. EDT, 11:00 p.m. AEST)\n\nJefferies Global Healthcare Conference\nDate: June 3, 2026\nTime: 11:40 a.m. EDT (1:40 a.m. AEST, June 4)\n\nEach session will be webcast live, and accessible through Telix’s Investor\nRelations website.\n\nFor more information including how to register, please visit:\nhttps://ir.telixpharma.com/events-presentations.\n\nAbout Telix Pharmaceuticals Limited\n\nTelix is a global biopharmaceutical company focused on the development and\ncommercialization of radiopharmaceuticals with the goal of addressing\nsignificant unmet medical need in oncology and rare diseases. Telix is\nheadquartered in Melbourne (Australia) with international operations in the\nUnited States, United Kingdom, Brazil, Canada, Europe (Belgium and\nSwitzerland) and Japan. Telix is listed on the Australian Securities Exchange\n(ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).\n\nVisit www.telixpharma.com for further information about Telix, including\ndetails of the latest share price, ASX and U.S. Securities and Exchange\nCommission (SEC) filings, investor and analyst presentations, news releases,\nevent details and other publications that may be of interest. You can also\nfollow Telix on LinkedIn\n(https://www.globenewswire.com/Tracker?data=IiWFlX2ktCyVv51Ylv1BJXZeB6xZDnX2jQEBWyUpLITDGOmV4Q-4fa9x74qW9GbvwQjhBsl5tWVyWCDUvP5Dj_dgCX3Jdu_9iFn0QI3Gcso=),\nX\n(https://www.globenewswire.com/Tracker?data=q2j-Bc3T2Bg-b5YaMID5g3kZlac2SLgsJ-N_5FfB6LArtFwadOlyLGygNKi54T4XM0GPtRP0IHtxSEN7kbXeAg==)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=6mLIRuxR6Nmyh-i4eIH4Kf2DU-I5PprS1K8Q0W4yXFoRtQ6YdmCDcCAk--BxPiWLB2_CMBu9jq0KjZNaf0sfXs6aTBvH3eKulg_K8ILflHk=).\n\n Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com \n \n Media Contact Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com \n \n\nLegal Notices\n\nCautionary Statement Regarding Forward-Looking Statements.\n\nYou should read this announcement together with our risk factors, as disclosed\nin our most recently filed reports with the Australian Securities Exchange\n(ASX), U.S. Securities and Exchange Commission (SEC), including our Annual\nReport on Form 20-F filed with the SEC, or on our website.\n\nThe information contained in this announcement is not intended to be an offer\nfor subscription, invitation or recommendation with respect to securities of\nTelix Pharmaceuticals Limited (Telix) in any jurisdiction, including the\nUnited States. The information and opinions contained in this announcement are\nsubject to change without notification. To the maximum extent permitted by\nlaw, Telix disclaims any obligation or undertaking to update or revise any\ninformation or opinions contained in this announcement, including any\nforward-looking statements (as referred to below), whether as a result of new\ninformation, future developments, a change in expectations or assumptions, or\notherwise. No representation or warranty, express or implied, is made in\nrelation to the accuracy or completeness of the information contained or\nopinions expressed in the course of this announcement.\n\nThis announcement may contain forward-looking statements, including within the\nmeaning of the U.S. Private Securities Litigation Reform Act of 1995, that\nrelate to anticipated future events, financial performance, plans, strategies\nor business developments. Forward-looking statements can generally be\nidentified by the use of words such as “may”, “expect”, “intend”,\n“plan”, “estimate”, “anticipate”, “believe”, “outlook”,\n“forecast” and “guidance”, or the negative of these words or other\nsimilar terms or expressions. Forward-looking statements involve known and\nunknown risks, uncertainties and other factors that may cause our actual\nresults, levels of activity, performance or achievements to differ materially\nfrom any future results, levels of activity, performance or achievements\nexpressed or implied by these forward-looking statements. Forward-looking\nstatements are based on Telix’s good-faith assumptions as to the financial,\nmarket, regulatory and other risks and considerations that exist and affect\nTelix’s business and operations in the future and there can be no assurance\nthat any of the assumptions will prove to be correct. In the context of\nTelix’s business, forward-looking statements may include, but are not\nlimited to, statements about: the initiation, timing, progress, completion and\nresults of Telix’s preclinical and clinical trials, and Telix’s research\nand development programs; Telix’s ability to advance product candidates\ninto, enroll and successfully complete, clinical studies, including\nmulti-national clinical trials; the timing or likelihood of regulatory filings\nand approvals for Telix’s product candidates, including TLX101-Px and\nTLX250-Px, manufacturing activities and product marketing activities;\nTelix’s sales, marketing and distribution and manufacturing capabilities and\nstrategies; the commercialization of Telix’s product candidates, if or when\nthey have been approved; Telix’s ability to obtain an adequate supply of raw\nmaterials at reasonable costs for its products and product candidates;\nestimates of Telix’s expenses, future revenues and capital requirements;\nTelix’s financial performance; developments relating to Telix’s\ncompetitors and industry; the anticipated impact of U.S. and foreign tariffs\nand other macroeconomic conditions on Telix’s business, including as a\nresult of war or other geopolitical conflicts; and the pricing and\nreimbursement of Telix’s product candidates, if and after they have been\napproved. Telix’s actual results, performance or achievements may be\nmaterially different from those which may be expressed or implied by such\nstatements, and the differences may be adverse. Accordingly, you should not\nplace undue reliance on these forward-looking statements.\n\nTrademarks and Trade Names. All trademarks and trade names referenced in this\npress release are the property of Telix Pharmaceuticals Limited (Telix) or,\nwhere applicable, the property of their respective owners. For convenience,\ntrademarks and trade names may appear without the ® or ™ symbols. Such\nomissions are not intended to indicate any waiver of rights by Telix or the\nrespective owners. Trademark registration status may vary from country to\ncountry. Telix does not intend the use or display of any third-party\ntrademarks or trade names to imply any affiliation with, endorsement by, or\nsponsorship from those third parties.\n\n©2026 Telix Pharmaceuticals Limited. All rights reserved.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/77ceffdf-31cc-415f-9747-efee950af329)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbHXx7k","title":"Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences","author":"Globe Newswire","ticker":"TLX","created":"2026-05-27T11:00:02.592Z","tickers":["TLX"],"exchange":"NASDAQ","article_body":"MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix\nPharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr.\nChristian Behrenbruch, Managing Director and Group CEO, will participate in\nthe upcoming William Blair 46(th) Annual Growth Stock Conference in Chicago,\nIL and in the Jefferies Global Healthcare Conference in New York, NY.\n\nPresentation details:\n\nWilliam Blair 46th Annual Growth Stock Conference\nDate: June 2, 2026\nTime: 8:00 a.m. CDT (9:00 a.m. EDT, 11:00 p.m. AEST)\n\nJefferies Global Healthcare Conference\nDate: June 3, 2026\nTime: 11:40 a.m. EDT (1:40 a.m. AEST, June 4)\n\nEach session will be webcast live, and accessible through Telix’s Investor\nRelations website.\n\nFor more information including how to register, please visit:\nhttps://ir.telixpharma.com/events-presentations.\n\nAbout Telix Pharmaceuticals Limited\n\nTelix is a global biopharmaceutical company focused on the development and\ncommercialization of radiopharmaceuticals with the goal of addressing\nsignificant unmet medical need in oncology and rare diseases. Telix is\nheadquartered in Melbourne (Australia) with international operations in the\nUnited States, United Kingdom, Brazil, Canada, Europe (Belgium and\nSwitzerland) and Japan. Telix is listed on the Australian Securities Exchange\n(ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).\n\nVisit www.telixpharma.com for further information about Telix, including\ndetails of the latest share price, ASX and U.S. Securities and Exchange\nCommission (SEC) filings, investor and analyst presentations, news releases,\nevent details and other publications that may be of interest. You can also\nfollow Telix on LinkedIn\n(https://www.globenewswire.com/Tracker?data=IiWFlX2ktCyVv51Ylv1BJXZeB6xZDnX2jQEBWyUpLITDGOmV4Q-4fa9x74qW9GbvwQjhBsl5tWVyWCDUvP5Dj_dgCX3Jdu_9iFn0QI3Gcso=),\nX\n(https://www.globenewswire.com/Tracker?data=q2j-Bc3T2Bg-b5YaMID5g3kZlac2SLgsJ-N_5FfB6LArtFwadOlyLGygNKi54T4XM0GPtRP0IHtxSEN7kbXeAg==)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=6mLIRuxR6Nmyh-i4eIH4Kf2DU-I5PprS1K8Q0W4yXFoRtQ6YdmCDcCAk--BxPiWLB2_CMBu9jq0KjZNaf0sfXs6aTBvH3eKulg_K8ILflHk=).\n\n Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com \n \n Media Contact Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com \n \n\nLegal Notices\n\nCautionary Statement Regarding Forward-Looking Statements.\n\nYou should read this announcement together with our risk factors, as disclosed\nin our most recently filed reports with the Australian Securities Exchange\n(ASX), U.S. Securities and Exchange Commission (SEC), including our Annual\nReport on Form 20-F filed with the SEC, or on our website.\n\nThe information contained in this announcement is not intended to be an offer\nfor subscription, invitation or recommendation with respect to securities of\nTelix Pharmaceuticals Limited (Telix) in any jurisdiction, including the\nUnited States. The information and opinions contained in this announcement are\nsubject to change without notification. To the maximum extent permitted by\nlaw, Telix disclaims any obligation or undertaking to update or revise any\ninformation or opinions contained in this announcement, including any\nforward-looking statements (as referred to below), whether as a result of new\ninformation, future developments, a change in expectations or assumptions, or\notherwise. No representation or warranty, express or implied, is made in\nrelation to the accuracy or completeness of the information contained or\nopinions expressed in the course of this announcement.\n\nThis announcement may contain forward-looking statements, including within the\nmeaning of the U.S. Private Securities Litigation Reform Act of 1995, that\nrelate to anticipated future events, financial performance, plans, strategies\nor business developments. Forward-looking statements can generally be\nidentified by the use of words such as “may”, “expect”, “intend”,\n“plan”, “estimate”, “anticipate”, “believe”, “outlook”,\n“forecast” and “guidance”, or the negative of these words or other\nsimilar terms or expressions. Forward-looking statements involve known and\nunknown risks, uncertainties and other factors that may cause our actual\nresults, levels of activity, performance or achievements to differ materially\nfrom any future results, levels of activity, performance or achievements\nexpressed or implied by these forward-looking statements. Forward-looking\nstatements are based on Telix’s good-faith assumptions as to the financial,\nmarket, regulatory and other risks and considerations that exist and affect\nTelix’s business and operations in the future and there can be no assurance\nthat any of the assumptions will prove to be correct. In the context of\nTelix’s business, forward-looking statements may include, but are not\nlimited to, statements about: the initiation, timing, progress, completion and\nresults of Telix’s preclinical and clinical trials, and Telix’s research\nand development programs; Telix’s ability to advance product candidates\ninto, enroll and successfully complete, clinical studies, including\nmulti-national clinical trials; the timing or likelihood of regulatory filings\nand approvals for Telix’s product candidates, including TLX101-Px and\nTLX250-Px, manufacturing activities and product marketing activities;\nTelix’s sales, marketing and distribution and manufacturing capabilities and\nstrategies; the commercialization of Telix’s product candidates, if or when\nthey have been approved; Telix’s ability to obtain an adequate supply of raw\nmaterials at reasonable costs for its products and product candidates;\nestimates of Telix’s expenses, future revenues and capital requirements;\nTelix’s financial performance; developments relating to Telix’s\ncompetitors and industry; the anticipated impact of U.S. and foreign tariffs\nand other macroeconomic conditions on Telix’s business, including as a\nresult of war or other geopolitical conflicts; and the pricing and\nreimbursement of Telix’s product candidates, if and after they have been\napproved. Telix’s actual results, performance or achievements may be\nmaterially different from those which may be expressed or implied by such\nstatements, and the differences may be adverse. Accordingly, you should not\nplace undue reliance on these forward-looking statements.\n\nTrademarks and Trade Names. All trademarks and trade names referenced in this\npress release are the property of Telix Pharmaceuticals Limited (Telix) or,\nwhere applicable, the property of their respective owners. For convenience,\ntrademarks and trade names may appear without the ® or ™ symbols. Such\nomissions are not intended to indicate any waiver of rights by Telix or the\nrespective owners. Trademark registration status may vary from country to\ncountry. Telix does not intend the use or display of any third-party\ntrademarks or trade names to imply any affiliation with, endorsement by, or\nsponsorship from those third parties.\n\n©2026 Telix Pharmaceuticals Limited. All rights reserved.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/77ceffdf-31cc-415f-9747-efee950af329)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-27T11:00:02.858357388Z","server_sent_at_ms":1779879602858},"received_at":"2026-05-27T11:00:03.006Z","source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301768/0/en/Telix-to-Participate-in-William-Blair-Growth-Stock-and-Jefferies-Global-Healthcare-Conferences.html"},"analysis":{"id":"35545","press_release_id":"46113","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Telix Pharmaceuticals announced that CEO Christian Behrenbruch will present at two upcoming investor conferences.\n\nThe William Blair 46th Annual Growth Stock Conference takes place on June 2, 2026, in Chicago.\n\nThe Jefferies Global Healthcare Conference follows on June 3, 2026, in New York. Both sessions will be webcast live via the company's Investor Relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference schedule update -- no new material information."},"keyFigures":{},"quotedText":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46(th) Annual Growth Stock Conference in Chicago, IL and in the Jefferies Global Healthcare Conference in New York, NY.","namedEntities":{"people":[{"name":"Christian Behrenbruch","role":"Managing Director and Group CEO"},{"name":"Kyahn Williamson","role":"SVP Investor Relations and Corporate Communications"},{"name":"Charlene Jaw","role":"Associate Director Investor Relations"},{"name":"Annie Kasparian","role":"Director Investor Relations and Corporate Communications"},{"name":"Eliza Schleifstein","role":"Media Contact"}],"products":[],"companies":[{"name":"Telix Pharmaceuticals Limited","ticker":"TLX","relationship":"filer"},{"name":"William Blair","relationship":"conference organizer"},{"name":"Jefferies","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of upcoming investor conference presentations. No new financial data, clinical results, or strategic changes disclosed. Standard corporate communications activity."},"tickerRelevance":{"others":[],"primary":"TLX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"routine_ir_activity","sectorWeight":"healthcare","householdBrandBoost":0,"marketCapAdjustment":0,"retailFavoriteBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Telix Pharmaceuticals announced that CEO Christian Behrenbruch will present at two upcoming investor conferences.\n\nThe William Blair 46th Annual Growth Stock Conference takes place on June 2, 2026, in Chicago.\n\nThe Jefferies Global Healthcare Conference follows on June 3, 2026, in New York. Both sessions will be webcast live via the company's Investor Relations website.","key_figures":{},"named_entities":{"people":[{"name":"Christian Behrenbruch","role":"Managing Director and Group CEO"},{"name":"Kyahn Williamson","role":"SVP Investor Relations and Corporate Communications"},{"name":"Charlene Jaw","role":"Associate Director Investor Relations"},{"name":"Annie Kasparian","role":"Director Investor Relations and Corporate Communications"},{"name":"Eliza Schleifstein","role":"Media Contact"}],"products":[],"companies":[{"name":"Telix Pharmaceuticals Limited","ticker":"TLX","relationship":"filer"},{"name":"William Blair","relationship":"conference organizer"},{"name":"Jefferies","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-27T11:05:25.456Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"routine_ir_activity","sectorWeight":"healthcare","householdBrandBoost":0,"marketCapAdjustment":0,"retailFavoriteBoost":0}},"durationMs":17702,"modelName":"george-droid-qwen-72b"}}